Clinical trials: Dementia, Senile
- Condition Dementia, Senile
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)
The proposed study is designed to evaluate the performance of the ALTOIDA™ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Memory Disorders, Cognitive Impairment
- Trial name
- AltoidaML (NCT02843529)
- Testing
- Altoida: neuropsychological, MRI, EEG and CSF biomarkers
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Altoida
Alzheimer Disease
Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients
To assess the pharmacodynamics (PD) of biomarkers amyloid beta peptide 40 and 42 (Ab40 and Ab42) in CSF, following single oral doses of GSI-953, an investigational drug, in healthy young subjects and patients with Alzheimer…
- Trial name
- NCT00479219
- Testing
- GSI-953
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer s Disease, MCI Conversion to Dementia
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
- Conditions
- Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
- Trial name
- NCT07701161
- Where
- 5 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Neurogen Biomarking LLC
Alzheimer Disease, Progressive Supranuclear Palsy
Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls
This is an experimental medicine study to evaluate the kinetics of cerebrospinal fluid (CSF) biomarkers in subjects with Alzheimer's disease (AD) or progressive supranuclear palsy (PSP) compared to healthy controls using a heavy…
- Trial name
- NCT01348061
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- KineMed
Substance Use Disorder (SUD)
A Study of a Mobile Phone Application Measuring the Eyes Before and After Medication
This is a post-market clinical follow-up study on an approved CE-marked eHealth system where a mobile phone application is used to measure the pupils and eye measurements to monitor the use of different drug substances.
- Trial name
- NCT06629740
- Testing
- Measurements with a eHealth system
- Where
- Netherlands
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Kontigo Care AB
Alzheimer Disease
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease
ASN51-101 is a randomized, double-blind, placebo-controlled, phase 1 first in human (FIH) safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) study of oral ASN51 in healthy young adult and elderly subjects and…
- Trial name
- NCT04759365
- Testing
- ASN51
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Asceneuron Pty Ltd.
AD - Alzheimer's Disease, MCI
A Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy
This is a non randomized, open-label Phase I study in Chinese participants. The goal of this clinical trial is to evaluate the safety and tolerability of a radioactive imaging agent called [18F]Flortaucipir Injection, which is…
- Trial name
- NCT07580703
- Testing
- [18F]Flortaucipir Injection
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Radiopharma
Alzheimer Disease, Amyloid
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein…
- Conditions
- Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
- Trial name
- NCT07787169
- Testing
- LY4405094, Florbetapir F18, Florbetaben F 18
- Where
- 19 sites in United States, China and 1 more
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Improved Diagnosis of Alzheimer's Disease Using the Synchronous Neural Interaction™ Test
This study is designed to test the hypothesis that the Synchronous Neural Interaction™ Test is useful for diagnosing Probable Alzheimer's Disease according to standard criteria.
- Trial name
- NCT00666445
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Orasi Medical, Inc.
Cognitive Impairment
Ascending Dose Study of CT1812 in Healthy Volunteers
This is a double-blind, placebo controlled, ascending dose, multi-cohort trial. The study will be conducted in two phases: a single ascending dose (SAD) phase "Part A", followed by a multiple ascending dose (MAD) phase "Part B".
- Trial name
- NCT02570997
- Testing
- CT1812
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Cognition Therapeutics
Alzheimer Disease
Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects
This is an investigator-initiated clinical (IIT)study.The main purpose of this study was to evaluate the diagnostic efficacy of XTR006 PET qualitative reading and quantitative analysis in detecting mild cognitive…
- Trial name
- NCT06151808
- Testing
- XTR006
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Alzheimer Disease
Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy Adults
To assess the safety and tolerability of ascending single oral doses of SAM-315, an investigational drug, in healthy adult subjects.
- Trial name
- NCT00479440
- Testing
- SAM-315
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer's Disease and Related Dementia, Fall Injury
Fall Detection and Prevention for Memory Care Through Real-time Artificial Intelligence Applied to Video
The purpose of the research is to study a new safety monitoring system developed by SafelyYou to help care for a loved one with dementia. The goal is to provide better support for unwitnessed falls.
- Trial name
- NCT03685240
- Testing
- SafelyYou Fall Prevention System
- Where
- United States
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- SafelyYou
Alzheimer's Disease
A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects
This is a randomized, double-blind (Investigator and subject-blinded) placebo-controlled, multiple, ascending-dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy young and elderly…
- Trial name
- NCT02840279
- Testing
- BPN14770
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Tetra Discovery Partners
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects.
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06388551
- Testing
- LY03017
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Alzheimer Disease
Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects
The objective of this study is to investigate how quickly and to what extent the 14-Carbon labeled SAM-531 is absorbed into the bloodstream, converted and eliminated from the body after oral administration in healthy male…
- Trial name
- NCT00906191
- Testing
- SAM-531
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer's Disease
Florbetapir Calibration to the Centiloid Scale
This study is designed to demonstrate the conversion of florbetapir (18F) Positron Emission Tomography (PET) Standard Uptake Value ratio (SUVr) to Centiloid units.
- Trial name
- NCT02120664
- Testing
- Florbetapir (18F), 11C-PiB
- Where
- 2 sites in United States, Australia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG)
The current study is intended to enrich and extend the database of Alzheimer's Disease (AD) and healthy control (HC) MEG scans and will include patients meeting DSM-IV-TR criteria for dementia of Alzheimer's type, and age- and…
- Trial name
- NCT00973518
- Where
- 2 sites in United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Orasi Medical, Inc.
Alzheimer Disease, Dementia
Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers
This project is developing a novel disease-modifying compound for Alzheimer's disease (AD).
- Trial name
- NCT05817643
- Testing
- BMS-984923
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Allyx Therapeutics
Alzheimer Disease
A Study of NH280105 in Healthy Adult Participants
This is a Phase 1, randomized, double-blinded, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of…
- Trial name
- NCT06870058
- Testing
- NH280105- SAD, NH280105- MAD
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.